The Phosphoproteomics group is in charge of the Reverse Phase Protein Arrays (RPPA) facility that allows the identification of new disease biomarkers and new therapeutic targets in oncological and non oncological disease through phosphoproteomic profiling. We believe that monitoring the activation status of signal transduction pathways will be key to identify patient subgroups that can benefit from the use of specific kinase inhibitors and to point out proteins suitable for patient risk stratification and targeted therapy.
In recent years through RPPA we identified and then validated new potential biomarkers and therapeutic targets for B-ALL, T-ALL and AML pediatric patients. Specifically, in T-ALL we observed the hyperactivation of LCK kinase in patients more resistant to glucocorticoids and in ETP T-ALL, a subset of patients highly resistant to therapy. Finally, we are also investigating the combined metabolic and signaling inhibition approach in pediatric T-ALL.
The group is involved in several national and international collaborative studies focused on the phosphoproteomic profiling of different neoplastic and non neoplastic diseases
- Giulia Veltri
- Max Sandei
Selected PublicationsJin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, Johnson MR, Volk AG, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, Abshiru NA, Hijiya N, Peirs S, Vandamme N, Berx G, Goosens S, Marshall SA, Rendleman EJ, Takahashi YH, Wang L, Rawat R, Bartom ET, Collings CK, Van Vlierberghe P, Strikoudis A, Kelly S, Ueberheide B, Mantis C, Kandela I, Bourquin JP, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher NL, Weinstock J, Kumar S, Crispino JD, Shilatifard A, Ntziachristos P.. 2019. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T-cell leukemia. Clin Cancer Res, Jan 1;25(1):222-239
Serafin V, Capuzzo G, Milani G, Minuzzo SA, Pinazza M, Bortolozzi R, Bresolin S, Porcù E, Frasson C, Indraccolo S, Basso G, Accordi B. . 2017. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood, 130 (25), 2750-2761
Serafin V, Lissandron V, Buldini B, Bresolin S, Paganin M, Grillo F, Andriano N, Palmi C, Cazzaniga G, Marmiroli S, Conter V, Basso G, Accordi B.. 2017. Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor. Leukemia, Apr;31(4):1007-1011.
Pastò A*, Serafin V*, Pilotto G, Lago C, Bellio C, Trusolino L, Bertotti A, Hoey T, Plateroti M, Esposito G, Pinazza M, Agostini M, Nitti D, Amadori A, Indraccolo S. *co-first author. 2014. NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells. Cancer Res, 1;74(7):2106-18
Accordi B, Galla L, Milani G, Curtarello M, Serafin V, Lissandron V, Viola G, te Kronnie G, De Maria R, Petricoin EF 3rd, Liotta LA, Indraccolo S, Basso G.. 2013. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, Apr;27(5):1019-27.
Corso Stati Uniti, 4
Phone: +39 049 9640139
Fax: +39 049 9640101